<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antibiotic therapy for adults with neurosyphilis - Buitrago‐Garcia, D - 2019 | Cochrane Library</title> <meta content="Antibiotic therapy for adults with neurosyphilis - Buitrago‐Garcia, D - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011399.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antibiotic therapy for adults with neurosyphilis - Buitrago‐Garcia, D - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011399.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011399.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antibiotic therapy for adults with neurosyphilis" name="citation_title"/> <meta content="Diana Buitrago‐Garcia" name="citation_author"/> <meta content="dianacarbg@gmail.com" name="citation_author_email"/> <meta content="Arturo J Martí‐Carvajal" name="citation_author"/> <meta content="Iberoamerican Cochrane Network" name="citation_author_institution"/> <meta content="Adriana Jimenez" name="citation_author"/> <meta content="Fundación Universitaria de Ciencias de la Salud‐Hospital de San José" name="citation_author_institution"/> <meta content="Lucieni O Conterno" name="citation_author"/> <meta content="University of Campinas" name="citation_author_institution"/> <meta content="Rodrigo Pardo" name="citation_author"/> <meta content="Faculty of Medicine, Universidad Nacional de Colombia" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD011399.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/05/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011399.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011399.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011399.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti‐Bacterial Agents [*therapeutic use]; Ceftriaxone [therapeutic use]; Neurosyphilis [*drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011399.pub2&amp;doi=10.1002/14651858.CD011399.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="1ljSZou6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011399\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011399\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011399\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011399\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fr","th","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011399.pub2",title:"Antibiotic therapy for adults with neurosyphilis",firstPublishedDate:"May 27, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane STI Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011399.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011399.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011399.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011399.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011399.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011399.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011399.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011399.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011399.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011399.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5960 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011399.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/full#CD011399-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/full#CD011399-sec-0104"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/full#CD011399-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/full#CD011399-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/full#CD011399-sec-0046"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/full#CD011399-sec-0047"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/full#CD011399-sec-0073"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/full#CD011399-sec-0098"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/appendices#CD011399-sec-0109"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/table_n/CD011399StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/table_n/CD011399StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antibiotic therapy for adults with neurosyphilis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/information#CD011399-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Diana Buitrago‐Garcia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/information#CD011399-cr-0003">Arturo J Martí‐Carvajal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/information#CD011399-cr-0004">Adriana Jimenez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/information#CD011399-cr-0005">Lucieni O Conterno</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011399.pub2/information#CD011399-cr-0006">Rodrigo Pardo</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/information/en#CD011399-sec-0121">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 May 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011399.pub2">https://doi.org/10.1002/14651858.CD011399.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011399-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011399-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011399-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011399-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011399-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD011399-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011399-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011399-abs-0001" lang="en"> <section id="CD011399-sec-0001"> <h3 class="title" id="CD011399-sec-0001">Background</h3> <p>Neurosyphilis is an infection of the central nervous system, caused by <i>Treponema pallidum</i>, a spirochete capable of infecting almost any organ or tissue in the body causing neurological complications due to the infection. This disease is a tertiary manifestation of syphilis. The first‐line treatment for neurosyphilis is aqueous crystalline penicillin. However, in cases such as penicillin allergy, other regimes of antibiotic therapy can be used. </p> </section> <section id="CD011399-sec-0002"> <h3 class="title" id="CD011399-sec-0002">Objectives</h3> <p>To assess the clinical effectiveness and safety of antibiotic therapy for adults with neurosyphilis. </p> </section> <section id="CD011399-sec-0003"> <h3 class="title" id="CD011399-sec-0003">Search methods</h3> <p>We searched the Cochrane Library, CENTRAL, MEDLINE, Embase, LILACS, World Health Organization International Clinical Trials Registry Platform and Opengrey up to April 2019. We also searched proceedings of eight congresses to a maximum of 10 years, and we contacted trial authors for additional information. </p> </section> <section id="CD011399-sec-0004"> <h3 class="title" id="CD011399-sec-0004">Selection criteria</h3> <p>We included randomised clinical trials that included men and women, regardless of age, with definitive diagnoses of neurosyphilis, including HIV‐seropositive patients. We compared any antibiotic regime (concentration, dose, frequency, duration), compared to any other antibiotic regime for the treatment for neurosyphilis in adults. </p> </section> <section id="CD011399-sec-0005"> <h3 class="title" id="CD011399-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected eligible trials, extracted data, and evaluated risk of bias. We resolved disagreements by involving a third review author. For dichotomous data (serological cure, clinical cure, adverse events), we presented results as summary risk ratios (RR) with 95% confidence intervals (CI). We assessed the quality of evidence using the GRADE approach. </p> </section> <section id="CD011399-sec-0006"> <h3 class="title" id="CD011399-sec-0006">Main results</h3> <p>We identified one trial, with 36 participants​ diagnosed ​with syphilis and HIV. The participants were mainly men, with a median age of 34 years. This trial, ​funded by a pharmaceutical company, compared ceftriaxone in 18 participants (2 g daily for 10 days), with penicillin G, also in 18 participants (4 million/Units (MU)/intravenous (IV) every 4 hours for 10 days). The trial reported incomplete and inconclusive results. Three of 18 (16%) participants receiving ceftriaxone versus 2 of 18 (11%) receiving penicillin G achieved serological cure (RR 1.50; 95% CI: 0.28 to 7.93; 1 trial, 36 participants very low‐quality evidence); and 8 of 18 (44%) participants receiving ceftriaxone versus 2 of 18 (18%) participants receiving penicillin G achieved clinical cure (RR 4.00; 95% CI: 0.98 to 16.30; 1 trial, 36 participants very low‐quality evidence). Although more participants who received ceftriaxone achieved serological and clinical cure compared to those who received penicillin G, the evidence from this trial was insufficient to determine whether there was a difference between treatment with ceftriaxone or penicillin G. </p> <p>In this trial, the authors reported what would usually be adverse events as symptoms and signs in the follow‐up of participants. Furthermore, this trial did not evaluate recurrence of neurosyphilis, time to recovery nor quality of life. We judged risk of bias in this clinical trial to be unclear for random sequence generation, allocation, ​and blinding of participants, and high for incomplete outcome data, potential conflicts of interest (funding bias), and other bias, due to the lack of a sample size calculation. We rated the quality of evidence as very low. </p> </section> <section id="CD011399-sec-0007"> <h3 class="title" id="CD011399-sec-0007">Authors' conclusions</h3> <p>Due to low quality and insufficient evidence, it was not possible to determine whether there was a difference between treatment with ceftriaxone or Penicillin G. Also, the benefits to people without HIV and neurosyphilis are unknown, as is the ceftriaxone safety profile.Therefore, these results should be interpreted with caution. This conclusion does not mean that antibiotics should not be used for treating this clinical entity. This Cochrane Review has identified the need of adequately powered trials, which should be planned according to Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) recommendations, conducted and reported as recommended by the CONSORT statement. Furthermore, the outcomes should be based on patients' perspectives taking into account Patient‐Centered Outcomes Research Institute (PCORI) recommendations. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011399-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011399-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011399-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011399-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011399-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011399-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011399-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD011399-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011399-abs-0014">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011399-abs-0004" lang="en"> <h3>Antibiotic therapy for adults with neurosyphilis</h3> <p><b>Review Question</b> </p> <p>We reviewed the clinical effectiveness and safety of antibiotic therapy for adults with neurosyphilis. </p> <p><b>Background</b> </p> <p>Syphilis is a condition caused by a micro‐organism called <i>Treponema pallidum.</i> At any stage of syphilis an individual can acquire neurosyphilis, which is an infection of the central nervous system (brain and spinal cord). The infection can be spread throughout the central nervous system, causing complications in the brain and spine. It may occur during early or late syphilis and it can have severe consequences for patients. Research has shown that people who are also infected with HIV are more likely to get neurosyphilis. Antibiotics are used to treat neurosyphilis. The first option is aqueous crystalline penicillin. However, in some cases, such as penicillin allergy, other antibiotics can be used. </p> <p><b>Study characteristics</b> </p> <p>We searched the medical literature up to April 2019 for trials that evaluated the effectiveness and safety of drugs proposed for the management of neurosyphilis in adults. We found only one randomised clinical trial that met our criteria (patients are randomly put into groups to receive different treatments). This trial involved 36 adults with both syphilis and HIV, who were mainly men, with a median age of 34 years. The trial compared two drugs: ceftriaxone (2 g once daily), and penicillin G (4 million units every 4 hours for 10 days). It was funded by a pharmaceutical company. </p> <p><b>Key findings</b> </p> <p>The trial reported serological cure, which is a decrease in the levels of the infection shown by laboratory analysis of fluids in the brain and spinal cord (known as cerebrospinal fluids), and clinical cure, which is the absence of signs or symptoms of neurosyphilis. Only three of 18 participants receiving ceftriaxone and two of 18 participants receiving penicillin G achieved serological cure; and eight of 18 participants receiving ceftriaxone and two of 18 participants receiving penicillin G achieved clinical cure. </p> <p>There was not enough evidence to allow us to state if there is a difference between treatment with ceftriaxone or Penicillin G for neurosyphilis in adults. The outcomes evaluated could change when trials with a better design become available. Additionally, we did not identify any evidence related to the effectiveness and safety of other drugs proposed to manage this condition. </p> <p><b>Quality of evidence</b> </p> <p>The quality of the evidence was very low for the outcomes serological cure and clinical cure due to problems with the trial's design and methods, and because there was only a small number of participants. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011399-sec-0104" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011399-sec-0104"></div> <h3 class="title" id="CD011399-sec-0105">Implications for practice</h3> <section id="CD011399-sec-0105"> <p>Although the authors who published the only study included in this review state that ceftriaxone is an alternative to penicillin for the treatment of adults with neurosyphilis (<a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a>), the evidence we found is not clear and precise to support the use of ceftriaxone for neurosyphilis in adults. This conclusion is based on findings with a high risk of bias, imprecision of the outcomes evaluated, incomplete data reporting, and funding of the trial by the pharmaceutical industry. It is not possible to support or refute the ceftriaxone regime recommended to treat people with neurosyphilis. Also, the benefits to people without HIV and neurosyphilis are unknown, as is the ceftriaxone safety profile. </p> </section> <h3 class="title" id="CD011399-sec-0106">Implications for research</h3> <section id="CD011399-sec-0106"> <p>This Cochrane Review has identified a need for adequately powered, randomised clinical trials for assessing clinical effectiveness and harms of antibiotics for treating people with neurosyphilis. This would enable us to conduct a systematic review than would include more than one randomised clinical trial, which would allow us to present more conclusive results. Potential trials should be planned according to Standard Protocol Items: Recommendations for Interventional Trials <a href="http://www.spirit-statement.org/" target="_blank">SPIRIT</a>) recommendations and conducted and reported as recommended by the Consolidated Standards of Reporting Trials (<a href="http://www.consort-statement.org/" target="_blank">CONSORT</a>) statement. Furthermore, the outcomes should be based on patients' perspectives, taking into account Patient‐Centered Outcomes Research Institute (<a href="http://www.pcori.org/" target="_blank">PCORI</a>) recommendations. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011399-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011399-sec-0036"></div> <div class="table" id="CD011399-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ceftriaxone compared to penicillin G for neurosyphilis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ceftriaxone compared to penicillin G for neurosyphilis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with neurosyphilis<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> ceftriaxone<br/> <b>Comparison:</b> penicillin G </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with penicillin G</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ceftriaxone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serological cure</b><br/> assessed by decrease in the CSF VDRL titre<br/> Follow‐up: range 14 weeks‐52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000<br/> (31 to 881) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.50<br/> (0.28 to 7.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysis performed by ITT analysis. Trial only reported CSF decrease in 2 of 7 participants receiving ceftriaxone and 2 of 7 receiving penicillin </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical cure</b><br/> assessed by RPR decrease<br/> Follow‐up: range 14 weeks‐52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000<br/> (109 to 1811) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.00<br/> (0.98 to 16.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysis performed by ITT analysis. Trial reported improvement in RPR titres in 8 of 10 participants receiving ceftriaxone and 2 of 15 receiving penicillin </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b><br/> Any untoward medical occurrence regarding medications<br/> follow‐up: range 1 week‐52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial evaluated symptoms and signs in the included participants, but these were clinical characteristics of participants, and not defined as adverse events </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence of neurosyphilis</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>( studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to recovery</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>( studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>( studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals</b><br/> Follow‐up: range 1 week‐52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000<br/> (47 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.00<br/> (0.42 to 9.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <br/> <b>CI:</b> Confidence interval; <b>CSF:</b> cerebrospinal fluid; <b>ITT:</b> intention‐to‐treat; <b>RPR:</b> rapid plasma reagin; <b>RR:</b> Risk ratio; <b>VDRL</b>: Venereal Disease Research Laboratory </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels due to limitations in the trial design and execution of trials.<br/> <sup>2</sup>Downgraded two levels due to few events and incomplete data regarding outcome, 95% confidence interval was between 0.28 and 7.93.<br/> <sup>3</sup>Not all the participants received the exact same tests to determine microbiological and clinical cure. Also, the sample size was very small and there was a very low number of events, which had an impact on the precision of the effect estimates.<br/> <sup>4</sup>Downgraded two levels due to the small sample size and very low number of events, which had an impact on the precision of the effect estimates<br/> <sup>5</sup>Downgraded two levels due to few events and incomplete data regarding outcome, 95% confidence interval was between 0.98 and 16.30. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011399-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011399-sec-0037"></div> <section id="CD011399-sec-0038"> <h3 class="title" id="CD011399-sec-0038">Description of the condition</h3> <p>Neurosyphilis is a tertiary manifestation of syphilis, an infection of the central nervous system (CNS) caused by <i>Treponema pallidum</i> (<a href="./references#CD011399-bbs2-0020" title="Anonymous . Syphilis: an ancient disease in a modern era. Lancet2017; Vol. 389, issue 10078:1492. [PUBMED: 28422012] ">Anonymous 2017</a>; <a href="./references#CD011399-bbs2-0049" title="HookEW3rd . Syphilis. Lancet2017;389(10078):1550‐7. [PUBMED: 27993382] ">Hook 2017</a>)<i>.</i> It is a spirochete capable of infecting almost any organ or tissue in the body causing protean clinical manifestations (<a href="./references#CD011399-bbs2-0032" title="Cone‐SendínMA , Hernández‐FletaMA , Cárdenes‐SantanaMA , Amela‐PerisR . Neurosyphilis forms of presentation and clinical management [Neurosífilis: formas de presentación y manejo]. Revista Neurología2002;35(4):380‐6. ">Conde‐Sendín 2002</a>; <a href="./references#CD011399-bbs2-0072" title="PhilipS . Chapter 34. Spirochetal infections. In: PapadakisMA , McPheeSJ , RabowMW editor(s). Current Medical Diagnosis and Treatment. New York: McGraw‐Hill Medical, 2014. ">Philip 2014</a>). The spirochete can be disseminated systemically causing neurological complications. It may occur during early or late syphilis (<a href="./references#CD011399-bbs2-0023" title="BergerJR , DeanD . Neurosyphilis. Handbook of Clinical Neurology2014;121:1461‐72. [PUBMED: 24365430] ">Berger 2014</a>). There are two forms of neurosyphilis: an early form that usually affects the cerebrospinal fluid (CSF), meninges, and vasculature, and the late form, which affects the brain and spinal cord parenchyma (<a href="./references#CD011399-bbs2-0078" title="RowlandLP , PedleyTA , MerrittHH . Merritt's Neurology. Lippincott Williams &amp; Wilkins, 2010. ">Rowland 2010</a>). In many cases it goes unnoticed although approximately one‐third of people infected with <i>T pallidum</i> display CSF abnormalities, such as pleocytosis, elevated protein concentration or reactivity for serological test, suggestive of CNS invasion by <i>T pallidum</i>. Between 1% and 5% of people with neurosyphilis develop neurological symptoms (<a href="./references#CD011399-bbs2-0023" title="BergerJR , DeanD . Neurosyphilis. Handbook of Clinical Neurology2014;121:1461‐72. [PUBMED: 24365430] ">Berger 2014</a>; <a href="./references#CD011399-bbs2-0062" title="MarraC . Update on neurosyphilis. Current Infectious Disease Reports2009;11(2):127‐34. [DOI: 10.1007/s11908‐009‐0019‐1] ">Marra 2009</a>; <a href="./references#CD011399-bbs2-0071" title="O'DonnellJA , EmeryCL . Neurosyphilis: a current review. Current Infectious Disease Reports2005;7(4):277‐84. ">O'Donnell 2005</a>). </p> <p>The epidemiology of neurosyphilis has largely paralleled that of syphilis in general (<a href="./references#CD011399-bbs2-0023" title="BergerJR , DeanD . Neurosyphilis. Handbook of Clinical Neurology2014;121:1461‐72. [PUBMED: 24365430] ">Berger 2014</a>; <a href="./references#CD011399-bbs2-0087" title="UnemoM , BradshawCS , HockingJS , DeVriesHJ , FrancisSC , MabeyD , et al. Sexually transmitted infections: challenges ahead. Lancet Infectious Diseases2017;17(8):e235‐e279. [PUBMED: 28701272] ">Unemo 2017</a>). By the early 1950s, a dramatic decline occurred as a consequence of the widespread use of antibiotics (<a href="./references#CD011399-bbs2-0023" title="BergerJR , DeanD . Neurosyphilis. Handbook of Clinical Neurology2014;121:1461‐72. [PUBMED: 24365430] ">Berger 2014</a>). However, incidence has increased due to the onset of the AIDs pandemic (<a href="./references#CD011399-bbs2-0029" title="ChenXS . Challenges in responses to syphilis epidemic. Lancet Infectious Diseases2017;17(8):793‐4. [PUBMED: 28701274] ">Chen 2017</a>; <a href="./references#CD011399-bbs2-0053" title="KentME , RomanelliF . Reexamining syphilis: an update on epidemiology, clinical manifestations, and management. Annals of Pharmacotherapy2008;42(2):226‐36. [PUBMED: 18212261] ">Kent 2008</a>; <a href="./references#CD011399-bbs2-0088" title="Van derBijAK , StolteIG , CoutinhoRA , DukersNH . Increase of sexually transmitted infections, but not HIV, among young homosexual men in Amsterdam: are STIs still reliable markers for HIV transmission?. Sexually Transmitted Infections2005;81(1):34‐7. [PUBMED: 15681720] ">Van der Bij 2005</a>). Currently, early neurosyphilis is more common than late neurosyphilis, and it is most frequently seen in people with HIV infection (<a href="./references#CD011399-bbs2-0088" title="Van derBijAK , StolteIG , CoutinhoRA , DukersNH . Increase of sexually transmitted infections, but not HIV, among young homosexual men in Amsterdam: are STIs still reliable markers for HIV transmission?. Sexually Transmitted Infections2005;81(1):34‐7. [PUBMED: 15681720] ">Van der Bij 2005</a>). Worldwide, it was estimated that by 1999, 11.6 million new cases of syphilitic infection were occurring per year (<a href="./references#CD011399-bbs2-0023" title="BergerJR , DeanD . Neurosyphilis. Handbook of Clinical Neurology2014;121:1461‐72. [PUBMED: 24365430] ">Berger 2014</a>). In 1999, there were approximately 107,000 new cases in North America, 136,000 new cases in Western Europe, 3.8 million new cases in Sub‐Saharan Africa, 4 million cases in South Asia, and 2.9 million cases in Latin America (<a href="./references#CD011399-bbs2-0023" title="BergerJR , DeanD . Neurosyphilis. Handbook of Clinical Neurology2014;121:1461‐72. [PUBMED: 24365430] ">Berger 2014</a>). A study conducted in the Netherlands showed an incidence of neurosyphilis of 0.47 per 10,000 adults, about 60 new cases per year, and suggests that, given the frequency of atypical manifestations of the disease, reintroduction of screening for neurosyphilis has to be considered (<a href="./references#CD011399-bbs2-0034" title="Daey OuwensIM , KoedijkFD , FioletAT , VanVeenMG , Van denWijngaardKC , VerhoevenWM , et al. Neurosyphilis in the mixed urban‐rural community of the Netherlands. Acta Neuropsychiatrica2014;26(3):186‐92. [PUBMED: 25142195] ">Daey 2014</a>). </p> <p>Among clinical symptoms, the earliest manifestation of neurosyphilis is syphilitic meningitis, which typically occurs within the first 12 months of infection. The symptoms of syphilitic meningitis are headache, photophobia and stiff neck (<a href="./references#CD011399-bbs2-0023" title="BergerJR , DeanD . Neurosyphilis. Handbook of Clinical Neurology2014;121:1461‐72. [PUBMED: 24365430] ">Berger 2014</a>). Acute meningeal syphilis can occur early in syphilis infection and is a well‐described feature of secondary syphilis; hearing loss, tinnitus, and vertigo are symptoms that can be observed in 40% of people with secondary syphilis (<a href="./references#CD011399-bbs2-0023" title="BergerJR , DeanD . Neurosyphilis. Handbook of Clinical Neurology2014;121:1461‐72. [PUBMED: 24365430] ">Berger 2014</a>). Late neurological complications of syphilis, which present after long periods of latency, are caused by meningovascular, or parenchymal damage, or both. Vascular involvement leading to focal ischemia can present with neurological deficits, including hemiparesis, aphasia, and focal or generalised seizures (<a href="./references#CD011399-bbs2-0031" title="CohenSE , KlausnerJD , EngelmanJ , PhilipS . Syphilis in the modern era: an update for physicians. Infectious Disease Clinics of North America2013;27(4):705‐22. [PUBMED: 24275265] ">Cohen 2013</a>). General paresis is a chronic meningoencephalitis, with direct invasion of the cerebrum by <i>T pallidum</i>, which usually manifests after 15 to 20 years, and includes manifestations of progressive dementia with changes in personality, affect, sensorium, intellect, and speech (<a href="./references#CD011399-bbs2-0031" title="CohenSE , KlausnerJD , EngelmanJ , PhilipS . Syphilis in the modern era: an update for physicians. Infectious Disease Clinics of North America2013;27(4):705‐22. [PUBMED: 24275265] ">Cohen 2013</a>). The characteristics of neurosyphilis may be modified by the concomitant presence of immunosuppressive agents or conditions such as HIV/AIDS (<a href="./references#CD011399-bbs2-0091" title="ZetolaNM , KlausnerJD . Syphilis and HIV infection: an update. Clinical Infectious Diseases2007;44(9):1222‐8. [PUBMED: 17407043] ">Zetola 2007</a>). HIV infection may be associated with an increased risk of development of early neurological complications, likely due to the inability to control the CNS infection after invasion (<a href="./references#CD011399-bbs2-0091" title="ZetolaNM , KlausnerJD . Syphilis and HIV infection: an update. Clinical Infectious Diseases2007;44(9):1222‐8. [PUBMED: 17407043] ">Zetola 2007</a>). See <a href="./appendices#CD011399-sec-0110">Appendix 1</a> for medical terms. </p> <p>Diagnosis of neurosyphilis is based on serological tests that are divided into two categories: non‐treponemal and treponemal tests. All non‐treponemal tests measure immunoglobulin (Ig) G and IgM antiphospholipid, and all treponemal tests use <i>T pallidum</i> or its components as the antigen if lesion exudate or tissue are available (<a href="./references#CD011399-bbs2-0076" title="RatnamSam . The laboratory diagnosis of syphilis. Canadian Journal of Infectious Diseases &amp; Medical Microbiology2005;16(1):45‐51. ">Ratnam 2005</a>). The treponemal tests usually used for diagnosis of neurosyphilis are fluorescent treponemal antibody absorption test (FTA ABS) and serum microhemagglutination–<i>T pallidum</i> (MHA‐TP). Non‐treponemal tests used are plasma reagin (RPR), or Venereal Disease Research Laboratory (VDRL) (<a href="./references#CD011399-bbs2-0023" title="BergerJR , DeanD . Neurosyphilis. Handbook of Clinical Neurology2014;121:1461‐72. [PUBMED: 24365430] ">Berger 2014</a>). See <a href="./appendices#CD011399-sec-0111">Appendix 2</a> for details of the operative performance of each test. </p> <p>Aditionally, the diagnosis of neurosyphilis in patients with clinical manifestations of neurosyphilis uses CSF findings supported by other laboratory tests, such as positive VDRL or positive CSF FTA‐ABS, and white blood cell count (polymorphonuclear leucocytes and/or lymphocytes) greater than 5 m/µL or CSF protein greater than 0.45 g/µL or IgG Index greater than 0.6 (<a href="./references#CD011399-bbs2-0084" title="TimmermansM , CarrJ . Neurosyphilis in the modern era. Journal of Neurology, Neurosurgery &amp; Psychiatry2004;75(12):1727‐30. ">Timmermans 2004</a>). On the other hand, CSF should be examined in any patient with syphilis and any neurological or ophthalmic symptoms or signs (cognitive dysfunction, motor or sensory defects, visual or auditory symptoms, cranial nerve palsies, meningismus, etc.). A CSF examination should also be considered in patients who fail to respond to therapy with an appropriate decline in nontreponemal antibody titre (<a href="./references#CD011399-bbs2-0052" title="KatzAR , LeeMV , WassermanGM . Sexually transmitted disease (STD) update: a review of the CDC 2010 STD treatment guidelines and epidemiologic trends of common STDs in Hawai'i. Hawai'i Journal of Medicine &amp; Public Health2012;71(3):68‐73. ">Katz 2012</a>). See <a href="./appendices#CD011399-sec-0112">Appendix 3</a> for details of the criteria for neurosyphilis diagnosis. </p> <p>Four antibiotic groups are prescribed in adults with neurosyphilis: β‐lactam antibiotics, tetracyclines, macrolides. Additionally, chloramphenicol is used to treat the disease (<a href="./references#CD011399-bbs2-0023" title="BergerJR , DeanD . Neurosyphilis. Handbook of Clinical Neurology2014;121:1461‐72. [PUBMED: 24365430] ">Berger 2014</a>; <a href="./references#CD011399-bbs2-0032" title="Cone‐SendínMA , Hernández‐FletaMA , Cárdenes‐SantanaMA , Amela‐PerisR . Neurosyphilis forms of presentation and clinical management [Neurosífilis: formas de presentación y manejo]. Revista Neurología2002;35(4):380‐6. ">Conde‐Sendín 2002</a>). </p> </section> <section id="CD011399-sec-0039"> <h3 class="title" id="CD011399-sec-0039">Description of the intervention</h3> <section id="CD011399-sec-0040"> <h4 class="title">β‐lactam antibiotics</h4> <p>Since 1940, intramuscular penicillin G has been demonstrated to be clearly beneficial for serological and clinical cure for neurosyphilis (<a href="./references#CD011399-bbs2-0060" title="MahoneyJF , ArnoldRC , SternerBL , HarrisA , ZwallMR . Penicillin treatment of early syphilis: II. JAMA1984;251(15):2005‐10. ">Mahoney 1984</a>; <a href="./references#CD011399-bbs2-0041" title="GhanemKG . Review: neurosyphilis: a historical perspective and review. CNS Neuroscience &amp; Therapeutics2010;16(5):e157‐68. [PUBMED: 20626434] ">Ghanem 2010</a>). It is the first‐line option drug for treating people at any stage of syphilis, and remains as an effective first‐line treatment (<a href="./references#CD011399-bbs2-0023" title="BergerJR , DeanD . Neurosyphilis. Handbook of Clinical Neurology2014;121:1461‐72. [PUBMED: 24365430] ">Berger 2014</a>). The choice of preparation (i.e. benzathine, aqueous procaine, or aqueous crystalline), its dosage and the treatment duration are determined by the stage and manifestations of the disease (<a href="./references#CD011399-bbs2-0023" title="BergerJR , DeanD . Neurosyphilis. Handbook of Clinical Neurology2014;121:1461‐72. [PUBMED: 24365430] ">Berger 2014</a>). According to international guidelines for treating neurosyphilis, crystalline penicillin should be administered in doses of 24 million units intravenous from 10 to 14 days (<a href="./references#CD011399-bbs2-0021" title="ArcherG , PolkRE . Chapter 133. Treatment and prophylaxis of bacterial infections. In: LongoDL , FauciAS , KasperDL , HauserSL , JamesonJL , LoscalzoJ editor(s). Harrison's Principles of Internal Medicine. 18th Edition. New York: McGraw‐Hill Medical, 2011. ">Archer 2011</a>; <a href="./references#CD011399-bbs2-0027" title="Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. www.cdc.gov/std/syphilis/default.htm accessed (18 September 2018). ">CDC 2015</a>; <a href="./references#CD011399-bbs2-0039" title="FrenchP , GombergM , JanierM , SchmidtB , VanVoorst VaderP , YoungH , IUSTI . IUSTI: 2008 European Guidelines on the management of syphilis. International Journal of STD &amp; AIDS2009;20(5):300‐9. ">French 2009</a>). Procaine penicillin should be administered in doses of 2.4 million units intramuscular once daily plus probenecid 500 mg orally four times a day, both for 10 to 14 days. Some specialists administer benzathine penicillin but studies revealed that the drug levels in the CSF are too low to eliminate <i>T pallidum</i> (<a href="./references#CD011399-bbs2-0065" title="MohrJA , GriffithsW , JacksonR , SaadahH , BirdP , RiddleJ . Neurosyphilis and penicillin levels in cerebrospinal fluid. JAMA1976;236(19):2208‐9. ">Mohr 1976</a>; <a href="./references#CD011399-bbs2-0066" title="MusherDM . Neurosyphilis: diagnosis and response to treatment. Clinical Infectious Diseases2008;47(7):900‐2. ">Musher 2008</a>). </p> <p>This antimicrobial group is the most frequent elicitor of drug hypersensitivity reactions (<a href="./references#CD011399-bbs2-0028" title="ChambersHF . Protein synthesis inhibitors and miscellaneous antibacterial agents. In: HardmanJG , LimbirdLE editor(s). Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics. 10. New York: McGraw‐Hill Medical, 2001:1239‐71. [ISBN: 0‐07‐135469‐7] ">Chambers 2001</a>; <a href="./references#CD011399-bbs2-0085" title="TorresMJ , BlancaM . The complex clinical picture of beta‐lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, and clavams. Medical Clinics of North America2010;94(4):805‐20. [PUBMED: 20609864] ">Torres 2010</a>). However, β‐lactams are generally safe drugs; serious adverse events are rare, and allergy is over‐diagnosed. In fact, severe hypersensitivity reactions to benzathine penicillin are scarce, with an estimated incidence of three cases of anaphylaxis per 100,000 treated (<a href="./references#CD011399-bbs2-0040" title="GalvaoTF , SilvaMT , SerruyaSJ , NewmanLM , KlausnerJD , PereiraMG , et al. Safety of benzathine penicillin for preventing congenital syphilis: a systematic review. PLoS ONE2013;8(2):e56463‐. ">Galvao 2013</a>; <a href="./references#CD011399-bbs2-0055" title="Lagacé‐WiensP , RubinsteinE . Adverse reactions to beta‐lactam antimicrobials. Expert Opinion on Drug Safety2012;11(3):381‐99. [PUBMED: 22220627] ">Lagacé‐Wiens 2012</a>; <a href="./references#CD011399-bbs2-0074" title="PetriWAJr . Penicillins, cephalosporins, and other β‐lactam antibiotics. In: HardmanJG , LimbirdLE editor(s). Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics. 10th Edition. New York: McGraw‐Hill Medical, 2001:1189‐1218. [ISBN: 0‐07‐135469‐7] ">Pietri 2001</a>). There is a particular reaction in people with syphilis when they receive antibiotic, namely the Jarisch‐Herxheimer reaction. It is a transient immunological reaction, characterised by symptoms such as fever, chills, headache, myalgia, and exacerbation of existing cutaneous lesions. These clinical findings are manifested over a short‐term period, that is, 24 hours after starting treatment (<a href="./references#CD011399-bbs2-0022" title="BelumGR , BelumVR , Chaitanya ArudraSK , ReddyBS . The Jarisch‐Herxheimer reaction: revisited. Travel Medicine and Infectious Disease2013;11(4):231‐7. [PUBMED: 23632012] ">Belum 2013</a>). </p> <p>Ceftriaxone, a third‐generation cephalosporin, is another β‐lactam antibiotic used for treating people with neurosyphilis. It is active in vitro against <i>T pallidum</i> with a good blood–brain barrier penetration. Ceftriaxone should be administered in doses of 2 g daily intravenous or intramuscular for 10 to 14 days. It is considered as an alternative for neurosyphilis patients with penicillin allergy, when penicillin anaphylaxis is considered an absolute contraindication (<a href="./references#CD011399-bbs2-0074" title="PetriWAJr . Penicillins, cephalosporins, and other β‐lactam antibiotics. In: HardmanJG , LimbirdLE editor(s). Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics. 10th Edition. New York: McGraw‐Hill Medical, 2001:1189‐1218. [ISBN: 0‐07‐135469‐7] ">Pietri 2001</a>). Cross‐reactivity between penicillins and cephalosporins are overstated, indeed, the risk with third‐ and fourth‐generation cephalosporin is negligible (<a href="./references#CD011399-bbs2-0073" title="PichicheroME , CaseyJR . Safe use of selected cephalosporins in penicillin‐allergic patients: a meta‐analysis. Otolaryngology and Head and Neck Surgery2007;136(3):340‐7. [PUBMED: 17321857] ">Pichichero 2007</a>). </p> </section> <section id="CD011399-sec-0041"> <h4 class="title">Tetracyclines</h4> <p>Tetracyclines are active against <i>T pallidum</i> (<a href="./references#CD011399-bbs2-0035" title="DeckDH , WinstonLG . Chapter 44: Tetracyclines, macrolides, clindamycin, chloramphenicol, streptogramins, and oxazolidinones. In: KatzungBG , MastersSB , TrevorAJ editor(s). Basic and Clinical Pharmacology. 12. New York: McGraw‐Hill Medical, 2012. ">Deck 2012</a>). Doxycycline is considered an alternative regime for neurosyphilis treatment and can be used at 100 mg orally, twice a day, for 21 to 30 days. This drug is a second‐generation tetracycline with increased oral bioavailability and tissue penetration. Doxycycline is absorbed in the duodenum and effective concentrations may be achieved in the CSF in patients with neurological infections. Another option is tetracycline 500 mg orally, four times daily, for 30 days (<a href="./references#CD011399-bbs2-0090" title="YimCW , FlynnNM , FitzgeraldFT . Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis. Antimicrobial Agents and Chemotherapy1985;28(2):347‐8. [PUBMED: 3834836] ">Yim 1985</a>). The most common side effects are pill oesophagitis, photosensitivity, and staining of teeth and bone (<a href="./references#CD011399-bbs2-0037" title="EisenD . Doxycicline. In: GraysonLM , CroweS , McCarthyJS , MillsJ , MoutonJW , NorrbySR , et al. editor(s). Kucers' The Use of Antibiotics. 6th Edition. London, UK: Hodder Arnold, 2010:851‐69. ">Eisen 2010</a>). </p> </section> <section id="CD011399-sec-0042"> <h4 class="title">Macrolides</h4> <p>Erythromycin is active against <i>T pallidum</i> (<a href="./references#CD011399-bbs2-0035" title="DeckDH , WinstonLG . Chapter 44: Tetracyclines, macrolides, clindamycin, chloramphenicol, streptogramins, and oxazolidinones. In: KatzungBG , MastersSB , TrevorAJ editor(s). Basic and Clinical Pharmacology. 12. New York: McGraw‐Hill Medical, 2012. ">Deck 2012</a>). The recommended erythromycin regime for people with neurosyphilis is 500 mg orally, four times a day, for 30 days (<a href="./references#CD011399-bbs2-0023" title="BergerJR , DeanD . Neurosyphilis. Handbook of Clinical Neurology2014;121:1461‐72. [PUBMED: 24365430] ">Berger 2014</a>). The most frequent adverse events associated with this drug are anorexia, nausea, vomiting, diarrhoea, and gastrointestinal intolerance, which are due to a direct stimulation of intestinal motility, and are a common reason for discontinuing erythromycin and substituting with another antibiotic. Erythromycins can produce acute cholestatic hepatitis (fever, jaundice, impaired liver function), probably as a hypersensitivity reaction. Other allergic reactions include fever, eosinophilia, and rashes (<a href="./references#CD011399-bbs2-0035" title="DeckDH , WinstonLG . Chapter 44: Tetracyclines, macrolides, clindamycin, chloramphenicol, streptogramins, and oxazolidinones. In: KatzungBG , MastersSB , TrevorAJ editor(s). Basic and Clinical Pharmacology. 12. New York: McGraw‐Hill Medical, 2012. ">Deck 2012</a>). </p> </section> <section id="CD011399-sec-0043"> <h4 class="title">Chloramphenicol</h4> <p>Chloramphenicol has been used to treat neurosyphilis as an additional treatment option: 1 g endovenously for 14 days (<a href="./references#CD011399-bbs2-0019" title="AmbrosePJ . Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clinical Pharmacokinetics1984;9(3):222‐38. [PUBMED: 6375931] ">Ambrose 1984</a>; <a href="./references#CD011399-bbs2-0032" title="Cone‐SendínMA , Hernández‐FletaMA , Cárdenes‐SantanaMA , Amela‐PerisR . Neurosyphilis forms of presentation and clinical management [Neurosífilis: formas de presentación y manejo]. Revista Neurología2002;35(4):380‐6. ">Conde‐Sendín 2002</a>). However, it can cause disturbances in red cell maturation and irreversible aplastic anaemia (<a href="./references#CD011399-bbs2-0044" title="GuglielmoB . Anti‐infective chemotherapeutic &amp; antibiotic agents, chapter e1. In: PapadakisMA , McPheeSJ , RabowMW editor(s). Current Medical Diagnosis &amp; Treatment. New York: McGraw‐Hill Medical, 2014. ">Guglielmo 2014</a>). Due to the above, chloramphenicol is no longer available; it was withdrawn after a Food and Drug Administration (FDA) recommendation (<a href="./references#CD011399-bbs2-0038" title="Food , DrugAdministration . Determination that chloromycetin (chloramphenicol) capsules, 250 milligrams, were withdrawn from sale for reasons of safety or effectiveness. www.federalregister.gov/documents/2012/07/13/2012‐17091/determination‐that‐chloromycetin‐chloramphenicol‐capsules‐250‐milligrams‐were‐withdrawn‐from‐sale2012. ">FDA 2012</a>). </p> </section> </section> <section id="CD011399-sec-0044"> <h3 class="title" id="CD011399-sec-0044">How the intervention might work</h3> <p>The aim of neurosyphilis treatment is to obtain sufficiently high antibiotic levels in the CNS during the long and irregular time frame where the bacteria is reproducing. Therefore, the treatment should be long and antibiotic‐dose high (<a href="./references#CD011399-bbs2-0032" title="Cone‐SendínMA , Hernández‐FletaMA , Cárdenes‐SantanaMA , Amela‐PerisR . Neurosyphilis forms of presentation and clinical management [Neurosífilis: formas de presentación y manejo]. Revista Neurología2002;35(4):380‐6. ">Conde‐Sendín 2002</a>). </p> <p>The β‐lactam antibiotics share a common structure and mechanism of action: inhibition of synthesis of the bacterial peptidoglycan cell wall, which is essential for their normal growth and development (<a href="./references#CD011399-bbs2-0074" title="PetriWAJr . Penicillins, cephalosporins, and other β‐lactam antibiotics. In: HardmanJG , LimbirdLE editor(s). Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics. 10th Edition. New York: McGraw‐Hill Medical, 2001:1189‐1218. [ISBN: 0‐07‐135469‐7] ">Pietri 2001</a>). They inhibit the growth of sensitive bacteria by inactivating enzymes located in the bacterial cell membrane, called penicillin binding proteins (PBPs). Therapeutic concentrations of penicillins are achieved readily in tissues and in secretions such as joint fluid, pleural fluid, pericardial fluid, and bile. CSF penetration is poor except in the presence of inflammation. Penicillin concentration in the CSF is variable but it is less than 1% plasma when the meninges are normal (<a href="./references#CD011399-bbs2-0074" title="PetriWAJr . Penicillins, cephalosporins, and other β‐lactam antibiotics. In: HardmanJG , LimbirdLE editor(s). Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics. 10th Edition. New York: McGraw‐Hill Medical, 2001:1189‐1218. [ISBN: 0‐07‐135469‐7] ">Pietri 2001</a>). When there is inflammation, concentrations in CSF may increase to as high as 5% of the plasma value. Penicillins are eliminated rapidly, particularly by glomerular filtration and renal tubular secretion, such that their half‐lives in the body are short, typically 30 to 90 minutes, and require frequent administration when given parenterally. Probenecid blocks the renal tubular secretion of penicillin. Therefore, the concurrent administration of probenecid prolongs the elimination of penicillin G and, consequently, increases the serum concentrations. As a consequence, concentrations of these drugs in urine are high (<a href="./references#CD011399-bbs2-0059" title="MacdougallC . Beyond susceptible and resistant, Part I: treatment of infections due to Gram‐negative organisms with inducible beta‐lactamases. Journal of Pediatric Pharmacology and Therapeutics2011;16(1):23‐30. [PUBMED: 22477821] ">Macdougall 2011</a>). </p> <p>Among tetracyclines, doxycycline has the longest experience for the treatment of CNS infections. The lipophilic drug doxycycline is readily absorbed (&gt; 80%) after oral application (<a href="./references#CD011399-bbs2-0067" title="NauR , SörgelF , EiffertH . Penetration of drugs through the blood‐cerebrospinal fluid/blood‐brain barrier for treatment of central nervous system infections. Clinical Microbiology Reviews2010;23(4):858‐83. ">Nau 2010</a>). Tetracyclines are bacteriostatic antibiotics that inhibit protein synthesis by binding reversibly to 16S rRNA of the 30S ribosomal subunit (<a href="./references#CD011399-bbs2-0081" title="StammLV . Global challenge of antibiotic‐resistant Treponema pallidum. Antimicrobial Agents and Chemotherapy2010;54(2):583‐9. [PUBMED: 19805553] ">Stamm 2010</a>); tetracyclines have a 30% excretion though urine and faeces to 20% to 60% (<a href="./references#CD011399-bbs2-0017" title="AgwuhKN , MacGowanA . Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. Journal of Antimicrobial Chemotherapy2006;58(2):256‐65. [PUBMED: 16816396] ">Agwuh 2006</a>). On the other hand, erythromycin belongs to the macrolides group, antibiotics that are protein‐synthesis inhibitors; specifically, they block the peptidyl transferase region in domain V of 23S rRNA (<a href="./references#CD011399-bbs2-0081" title="StammLV . Global challenge of antibiotic‐resistant Treponema pallidum. Antimicrobial Agents and Chemotherapy2010;54(2):583‐9. [PUBMED: 19805553] ">Stamm 2010</a>). Macrolides penetrate well into tissue, but because of their relatively high molecular mass, and probably also because of their affinity for P‐glycoprotein, they do not reach sufficient CSF concentrations in the absence of meningeal inflammation. The excretion of erythromycin is mainly through faeces followed by urine: 2% to 5% as an unchanged molecule (<a href="./references#CD011399-bbs2-0067" title="NauR , SörgelF , EiffertH . Penetration of drugs through the blood‐cerebrospinal fluid/blood‐brain barrier for treatment of central nervous system infections. Clinical Microbiology Reviews2010;23(4):858‐83. ">Nau 2010</a>; <a href="./references#CD011399-bbs2-0083" title="ThompsonPJ , BurgessKR , MarlinGE . Influence of food on absorption of erythromycin ethyl succinate. Antimicrobial Agents and Chemotherapy1980;18(5):829‐31. [PUBMED: 6969579] ">Thompson 1980</a>). These groups of antibiotics inhibit the protein synthesis of <i>T pallidum</i> and interfere with protein synthesis in protein in human cells (<a href="./references#CD011399-bbs2-0058" title="LevinsonWE . Chapter 10. Antimicrobial drugs: mechanism of action. Review of Medical Microbiology and Immunology. Vol. 12th, New York: McGraw‐Hill Medical, 2012. ">Levinson 2012</a>). </p> </section> <section id="CD011399-sec-0045"> <h3 class="title" id="CD011399-sec-0045">Why it is important to do this review</h3> <p>Since 2000, incidence of early‐stage syphilis in the USA and Europe has increased (<a href="./references#CD011399-bbs2-0061" title="MarraCM , MaxwellCL , SmithSL , LukehartSA , RompaloAM , EatonM , et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. Journal of Infectious Diseases2004;189(3):369‐76. [PUBMED: 14745693] ">Marra 2004</a>). Adequate treatment for people with neurosyphilis is fundamental for prevention of neurological sequelae. According to international guidelines, aqueous crystalline penicillin is the first‐line treatment for neurosyphilis, while procaine penicillin plus probenecid, amoxicillin, ceftriaxone, and doxycycline could be used as alternative regimes when parenteral administration is not feasible (<a href="./references#CD011399-bbs2-0027" title="Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. www.cdc.gov/std/syphilis/default.htm accessed (18 September 2018). ">CDC 2015</a>; <a href="./references#CD011399-bbs2-0039" title="FrenchP , GombergM , JanierM , SchmidtB , VanVoorst VaderP , YoungH , IUSTI . IUSTI: 2008 European Guidelines on the management of syphilis. International Journal of STD &amp; AIDS2009;20(5):300‐9. ">French 2009</a>). Current recommendations are based on what is known about the pharmacokinetics of the available drugs, the effect on <i>T pallidum</i> in vitro, laboratory considerations, biological plausibility, expert opinion, case studies, and clinical experience (<a href="./references#CD011399-bbs2-0027" title="Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. www.cdc.gov/std/syphilis/default.htm accessed (18 September 2018). ">CDC 2015</a>). However, <i>T pallidum</i> is highly sensitive to penicillin, and <i>T pallidum</i> is capable of acquiring plasmids that produce the enzyme penicillinase. Clinical data are lacking on the optimal dose and duration of treatment and the long‐term efficacy of antimicrobials other than penicillin (<a href="./references#CD011399-bbs2-0027" title="Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. www.cdc.gov/std/syphilis/default.htm accessed (18 September 2018). ">CDC 2015</a>; <a href="./references#CD011399-bbs2-0054" title="KingstonM , FrenchP , GohB , GooldP , HigginsS , SukthankarA , et al. UK National Guidelines on the Management of Syphilis 2008. International Journal of STD &amp; AIDS2008;19(11):729‐40. [PUBMED: 18931264] ">Kingston 2008</a>). The safety profile in the treatment for neurosyphilis could bring many potential complications. Jarsich‐Herxheimer is one, but other adverse reactions are also associated with antibiotic administration (<a href="./references#CD011399-bbs2-0018" title="AliL , RoosKL . Antibacterial therapy of neurosyphilis: lack of impact of new therapies. CNS Drugs2002;16(12):799‐802. [PUBMED: 12421113] ">Ali 2002</a>; <a href="./references#CD011399-bbs2-0029" title="ChenXS . Challenges in responses to syphilis epidemic. Lancet Infectious Diseases2017;17(8):793‐4. [PUBMED: 28701274] ">Chen 2017</a>). In this scenario it is important to demonstrate what potential complications are associated with the treatment for neurosyphilis. </p> <p>When patients are immunocompromised, that is, patients with HIV infection, they have a higher likelihood of developing neurosyphilis (<a href="./references#CD011399-bbs2-0023" title="BergerJR , DeanD . Neurosyphilis. Handbook of Clinical Neurology2014;121:1461‐72. [PUBMED: 24365430] ">Berger 2014</a>). Penicillin remains the first choice of treatment for neurosyphilis, and research has shown that infectious disease specialists often treat secondary syphilis among HIV‐infected patients with three doses of benzathine penicillin G instead of one dose of penicillin, leading to a high probability of adverse effects, including allergic reaction, neurotoxicity, and neutropenia, among others (<a href="./references#CD011399-bbs2-0051" title="JinnoS , AnkerB , KaurP , BristowCC , KlausnerJD . Predictors of serological failure after treatment in HIV‐infected patients with early syphilis in the emerging era of universal antiretroviral therapy use. BMC Infectious Diseases2013;13:605. [PUBMED: 24369955] ">Jinno 2013</a>). Additionally, the CDC guideline states that patients with HIV might have higher rates of serological treatment failure with recommended regimens compared to those without HIV (<a href="./references#CD011399-bbs2-0027" title="Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. www.cdc.gov/std/syphilis/default.htm accessed (18 September 2018). ">CDC 2015</a>). Due to the above, it was necessary to know the clinical effectiveness of different therapies as an option to treat patients with neurosyphilis, and at the same time, there is a need to conduct a critical appraisal of the randomised clinical trials in this subgroup of patients (<a href="./references#CD011399-bbs2-0056" title="LassoMB , BalcellsME , FernándezAS , GaetePG , SerriMV , PérezJG , et al. Neurosyphilis in the patients with and without HIV infection: description and comparison of two historical cohorts [Neurosífilis en pacientes portadores y no portadores de VIH: descripción y comparación de dos cohortes históricas]. Revista Chilena de Infectología2009;26(6):540‐7. [20098789] ">Lasso 2009</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011399-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011399-sec-0046"></div> <p>To assess the clinical effectiveness and safety of antibiotic therapy for adults with neurosyphilis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011399-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011399-sec-0047"></div> <section id="CD011399-sec-0048"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011399-sec-0049"> <h4 class="title">Types of studies</h4> <p>We included randomised clinical trials with parallel design. We excluded quasi‐randomised trials because this type of study could bring effect estimates that indicate more extreme benefits when they are compared with randomised clinical trials (<a href="./references#CD011399-bbs2-0070" title="O’ConnorD , GreenS , Higgins JP(editors) . Chapter 5: Defining the review question and developing criteria for including studies. In: Higgins JPT, Green S (editors), Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">O'Connor 2011</a>). </p> </section> <section id="CD011399-sec-0050"> <h4 class="title">Types of participants</h4> <p>Men and women, regardless of age. We included people with a definitive diagnosis of neurosyphilis and, due to the absence of consensus on diagnostic criteria for neurosyphilis and HIV, and the complications of interpretation of CSF abnormalities when a HIV coinfection is present, we also included people who had a definitive diagnosis of neurosyphilis and who were also HIV‐seropositive (<a href="./references#CD011399-bbs2-0023" title="BergerJR , DeanD . Neurosyphilis. Handbook of Clinical Neurology2014;121:1461‐72. [PUBMED: 24365430] ">Berger 2014</a>). We adopted the recommendations for diagnosis of neurosyphilis in the phase of HIV infection detailed by <a href="./references#CD011399-bbs2-0023" title="BergerJR , DeanD . Neurosyphilis. Handbook of Clinical Neurology2014;121:1461‐72. [PUBMED: 24365430] ">Berger 2014</a> (see <a href="./appendices#CD011399-sec-0112">Appendix 3</a> for details). </p> </section> <section id="CD011399-sec-0051"> <h4 class="title">Types of interventions</h4> <p>Penicillin (any concentration, presentation frequency and duration), compared to any other antibiotic regime. </p> </section> <section id="CD011399-sec-0052"> <h4 class="title">Types of outcome measures</h4> <section id="CD011399-sec-0053"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011399-list-0001"> <li> <p>Serological cure: defined as a decrease in the CSF Venereal Disease Research Laboratory test (VDRL) titre by two dilutions or reversion to non‐reactive within two years after completion of therapy for patients with definitive diagnosis of syphilis (<a href="./references#CD011399-bbs2-0018" title="AliL , RoosKL . Antibacterial therapy of neurosyphilis: lack of impact of new therapies. CNS Drugs2002;16(12):799‐802. [PUBMED: 12421113] ">Ali 2002</a>; <a href="./references#CD011399-bbs2-0068" title="NayakS , AcharjyaB . VDRL test and its interpretation. Indian Journal of Dermatology2012;57(1):3‐8. [PUBMED: 22470199] ">Nayak 2012</a>). The CSF should be examined at the end of treatment to document a fall in cell count, and it should then be examined at six‐month intervals for two to three years. The leukocyte count should return to normal within one year of treatment (usually six months), and the protein level should return to normal within two years (<a href="./references#CD011399-bbs2-0023" title="BergerJR , DeanD . Neurosyphilis. Handbook of Clinical Neurology2014;121:1461‐72. [PUBMED: 24365430] ">Berger 2014</a>). </p> </li> <li> <p>Clinical cure: defined as continued absence of signs or symptoms, or the serum RPR decreasing by four‐fold within two years of treatment (<a href="./references#CD011399-bbs2-0024" title="BilgramiM , O'KeefeP . Chapter 90: Neurologic diseases in HIV‐infected patients. In: BillerJ , FerroJ editor(s). Neurologic Aspects of Systemic Disease Part III. Vol. 121, Elsevier, 2014:1321‐44. ">Bilgrami 2014</a>) </p> </li> <li> <p>Adverse events: in general defined by the International Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice (<a href="./references#CD011399-bbs2-0050" title="ICH‐GCP. Expert Working Group International Conference on Harmonisation. Guideline for Good Clinical Practice. CFR &amp; ICH Guidelines. Vol. 1, Pennsylvania: Barnett International ‐Parexel, 1997. ">ICH‐GCP 1997</a>), as any untoward medical occurrence that at any dose results in death, is life‐threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect. We considered all other adverse events as non‐serious (<a href="./references#CD011399-bbs2-0050" title="ICH‐GCP. Expert Working Group International Conference on Harmonisation. Guideline for Good Clinical Practice. CFR &amp; ICH Guidelines. Vol. 1, Pennsylvania: Barnett International ‐Parexel, 1997. ">ICH‐GCP 1997</a>). Within adverse events, we planned to describe reported outcomes, such as the Jarisch‐Herxheimer reaction, a common manifestation that is a transient immunological reaction characterised by constitutional symptoms such as fever, chills, headache, myalgias, and exacerbation of existing cutaneous lesions after the administration of β‐lactam antibiotics (<a href="./references#CD011399-bbs2-0022" title="BelumGR , BelumVR , Chaitanya ArudraSK , ReddyBS . The Jarisch‐Herxheimer reaction: revisited. Travel Medicine and Infectious Disease2013;11(4):231‐7. [PUBMED: 23632012] ">Belum 2013</a>). Also, we planned to describe other adverse events related to other antibiotic regimes administered, such as pill oesophagitis, photosensitivity, staining of teeth and bone in tetracycline administration, or fever, eosinophilia, and rashes in macrolides. </p> </li> </ul> </p> </section> <section id="CD011399-sec-0054"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011399-list-0002"> <li> <p>Recurrence of neurosyphilis: recurrent or persistent symptoms or a sustained four‐fold increase in non‐treponemal test titres despite appropriate treatment (<a href="./references#CD011399-bbs2-0026" title="BrownDL , FrankJE . Diagnosis and management of syphilis. American Family Physician2003;68(2):283‐90. [PUBMED: 12892348] ">Brown 2003</a>) </p> </li> <li> <p>Time to recovery: defined as the time to achieve clinical or serological cure</p> </li> <li> <p>Quality of life, according to the definition of the concept adopted in each trial and using any validated scale </p> </li> <li> <p>All causes of withdrawals: defined as any retirement of an individual in a trial</p> </li> </ul> </p> </section> </section> </section> <section id="CD011399-sec-0055"> <h3 class="title">Search methods for identification of studies</h3> <p>We used electronic searching in bibliographic databases and handsearching, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011399-bbs2-0057" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Lefebvre 2011</a>). We downloaded and managed the search results using the EndNote bibliographic software. </p> <section id="CD011399-sec-0056"> <h4 class="title">Electronic searches</h4> <p>We performed the search in collaboration with the Cochrane Sexually Transmitted Infections' (STI) Information Specialist and a healthcare librarian. We used a combination of exploded controlled vocabulary (MeSH, Emtree, DeCS), and free‐text terms (considering spelling variants, plurals, synonyms, acronyms, and abbreviations), for 'neurosyphilis' and 'antibiotic therapy', with field labels, truncation, proximity operators, and Boolean operators (see <a href="./appendices#CD011399-sec-0113">Appendix 4</a> for search strategies). </p> <p>We searched the following databases up to April 2019:</p> <p> <ul id="CD011399-list-0003"> <li> <p>the STI Specialised Register of trials;</p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 4), via OVID;</p> </li> <li> <p>Ovid MEDLINE (1946 to April 2019 );</p> </li> <li> <p>Embase Elsevier (1974 to April 2019);</p> </li> <li> <p>LILACS via iAHx interface (1982 to April 2019).</p> </li> </ul> </p> <p>We did not apply any restrictions on language or date.</p> <p>We also searched the following clinical trials registries:</p> <p> <ul id="CD011399-list-0004"> <li> <p>World Health Organization International Clinical Trials Registry Platform (ICTRP; <a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>) </p> </li> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>) </p> </li> </ul> </p> <p>We searched Open Grey (<a href="http://www.opengrey.eu/" target="_blank">www.opengrey.eu</a>) for grey literature. </p> </section> <section id="CD011399-sec-0057"> <h4 class="title">Searching other resources</h4> <p>We handsearched conference proceeding abstracts of the following events:</p> <p> <ul id="CD011399-list-0005"> <li> <p>International Society for Sexually Transmitted Diseases Research (ISSTDR; <a href="http://www.isstdr.org/" target="_blank">www.isstdr.org</a>), 2007, 2009, 2011, 2013, 2015 and 2017; </p> </li> <li> <p>British Association for Sexual Health and HIV (BASHH; <a href="http://www.bashh.org/" target="_blank">www.bashh.org</a>), 2004, 2006, 2007, 2009, 2014,2015,2016,20117 and 2018; </p> </li> <li> <p>International Congress on Infectious Diseases (ICID; <a href="http://www.isid.org/" target="_blank">www.isid.org</a>), 2010 and 2012; </p> </li> <li> <p>International Union against Sexually Transmitted Infections (IUSTI; <a href="http://www.iusti.org/" target="_blank">www.iusti.org</a>), 2011 and 2012; </p> </li> <li> <p>International Society for Infectious Diseases (ISID; <a href="http://www.isid.org/" target="_blank">www.isid.org</a>), 2011 and 2017; </p> </li> <li> <p>International Meeting on Emerging Diseases and Surveillance (IMED; <a href="http://www.isid.org/" target="_blank">www.isid.org</a>), 2007, 2009 and 2011; </p> </li> <li> <p>Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC; <a href="http://www.asm.org" target="_blank">www.asm.org</a>), 2011 and 2012; </p> </li> <li> <p>International Federation of Gynecology and Obstetrics (FIGO; <a href="https://www.figo.org/" target="_blank">www.figo.org</a>), 2015, 2018. </p> </li> </ul> </p> <p>We screened the reference lists of all selected trials. We contacted the main authors to identify any additional published or unpublished data. Additionally we searched other sources with the terms 'neurosyphilis', 'neurolues' and 'tabes dorsalis'. </p> </section> </section> <section id="CD011399-sec-0058"> <h3 class="title" id="CD011399-sec-0058">Data collection and analysis</h3> <section id="CD011399-sec-0059"> <h4 class="title">Selection of studies</h4> <p>We followed the methods for study selection by using the steps recommended by the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011399-bbs2-0047" title="HigginsJP , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011a</a>). Two review authors (DB, LOC) independently screened the titles and abstracts to identify potential trials for inclusion eligibility, using Early Review Organizing Software (EROS; <a href="./references#CD011399-bbs2-0030" title="CiapponiA , GlujovskyD , BardachA , García MartíS , ComandeD . EROS: a new software for early stage of systematic reviews. HTAi Conference, 8th annual meeting; 2011 June 27‐29; Rio de Janeiro. www.htai2011.org/documentos/HTAi_resumos_ISBN.pdf. Rio de Janeiro: Brazilian Ministry of Health, 2011. ">Ciapponi 2011</a>; <a href="./references#CD011399-bbs2-0042" title="GlujovskyD , BardachA , García‐MartíS , ComandéD , CiapponiA . PRM2 EROS: a new software for early stage of systematic reviews. Value in Health. Blackwell Science, 2011; Vol. 14, issue 7:A564. ">Glujovsky 2011</a>; <a href="./references#CD011399-bbs2-0063" title="McQuayHJ , MooreRA . An Evidence‐Based Resource for Pain Relief. Oxford: Oxford University Press, 1998. ">McQuay 1998</a>). When the screening was not satisfactory, based on the title and abstract, we obtained the full‐text article for assessment. We have presented the results of the trial selection as a PRISMA flowchart (<a href="./references#CD011399-bbs2-0064" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006‐12. [PUBMED: 19631508] ">Moher 2009</a>; <a href="#CD011399-fig-0001">Figure 1</a>). We resolved disagreements through discussion and consensus. A third review author (AMC) acted as referee when necessary. We contacted the trial authors to resolve doubts about available information or in case of disagreements. </p> <div class="figure" id="CD011399-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow of information through the different phases of the review" data-id="CD011399-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_n/nCD011399-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow of information through the different phases of the review</p> </div> </div> </div> </section> <section id="CD011399-sec-0060"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (DB, LOC) independently assessed for inclusion all the titles and abstracts of records retrieved from the search results. We resolved any disagreements through discussion or, if required, we consulted a third review author (AMC). </p> <section id="CD011399-sec-0061"> <h5 class="title">Data extraction format</h5> <p>We developed and piloted a standardised form to extract data. Two review authors (DB, LOC) independently extracted the following data from the included trials. </p> <p> <ul id="CD011399-list-0006"> <li> <p>Study location and setting</p> </li> <li> <p>Trial design and power calculation</p> </li> <li> <p>Ethical approval</p> </li> <li> <p>Inclusion and exclusion criteria</p> </li> <li> <p>Baseline characteristics of trial participants including sex, age, sexual orientation, pregnancy status for women, diagnostic test used to detect <i>T pallidum</i> </p> </li> <li> <p>Types of intervention: opportunistic or systematic invitation for screening; number of screening rounds, screening interval </p> </li> <li> <p>Types of comparison group: usual care, alternative screening method</p> </li> <li> <p>Types of outcome: primary, secondary</p> </li> <li> <p>Report of methodological characteristics (see <a href="#CD011399-sec-0062">Assessment of risk of bias in included studies</a> for details) </p> </li> <li> <p>Number of people assessed for eligibility</p> </li> <li> <p>Numbers randomised to intervention and comparison groups</p> </li> <li> <p>Numbers receiving screening in intervention and comparison groups (at each screening round if multiple rounds) </p> </li> <li> <p>Numbers included in analyses in intervention and comparison groups</p> </li> <li> <p>Numbers with outcomes in intervention and comparison groups</p> </li> </ul> </p> <p>One review author (DB) entered data into Review Manager 5 (<a href="./references#CD011399-bbs2-0077" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), and two review authors (AJ, AMC) independently checked for accuracy. When necessary, we also contacted the corresponding trial authors for further details. </p> </section> </section> <section id="CD011399-sec-0062"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (DB, LOC) independently assessed the risk of bias for each included study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011399-bbs2-0048" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). We resolved any discrepancies through discussion with AMC. Those assessing risk of bias are content and methodology experts. When we needed to obtain missing information, we contacted the trial authors using open‐ended questions. We assessed risk of bias in the included trials and collected information in data extraction forms. We then added the information to Review Manager 5 (<a href="./references#CD011399-bbs2-0077" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>) </p> <p>We assessed the following 'Risk of bias' domains, as set out in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011399-bbs2-0048" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). </p> <p> <ul id="CD011399-list-0007"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants, personnel</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other sources of bias</p> </li> </ul> </p> <p>We also applied the criteria defined by <a href="./references#CD011399-bbs2-0086" title="TramacereI , DelGiovaneC , SalantiG , D'AmicoR , FilippiniG . Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD011381.pub2] ">Tramacere 2015</a> for assessing the risk of bias. To summarise the quality of the evidence we considered allocation concealment, blinding of outcome assessor, and incomplete outcome data in order to classify each study as at: low risk of bias when we judged all of the three criteria as at low risk of bias; high risk of bias when we judged at least one criterion as at high risk of bias; unclear risk of bias when we judged all of the three criteria as at unclear risk of bias; and moderate risk of bias in the remaining cases. We assessed the overall risk of bias by outcome, taking into account the number the included studies with the outcome of interest and the sample size of the study. With reference to the first seven domains above, we assessed the likely magnitude and direction of the bias and whether we considered it was likely to affect the findings. </p> </section> <section id="CD011399-sec-0063"> <h4 class="title">Measures of treatment effect</h4> <p>We expected to find dichotomous data regarding (serological cure, clinical cure, adverse events, recurrence of neurosyphilis, withdrawals). However, we only found results regarding serological cure, clinical cure, adverse events. We presented results as summary risk ratios (RR) with 95% confidence intervals (CIs). The RR as a relative effect measure has consistency, works well with a low or high rate of events, and is easy to interpret and use in clinical practice. </p> </section> <section id="CD011399-sec-0064"> <h4 class="title">Unit of analysis issues</h4> <p>When we identified a clinical trial that randomly assigned participants into several intervention groups, we considered the control group to be the group that was receiving β‐lactam antibiotic regime and the intervention group to be the group that was receiving other antibiotic schemes in the management of adults with neurosyphilis. </p> </section> <section id="CD011399-sec-0065"> <h4 class="title">Dealing with missing data</h4> <p>In the case of missing data on participants or missing statistics (such as standard deviations), we contacted the trial authors. </p> </section> <section id="CD011399-sec-0066"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess statistical heterogeneity by graphical interpretation and with an I<sup>2</sup> statistic (<a href="./references#CD011399-bbs2-0045" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>), and Chi<sup>2</sup> test (<a href="./references#CD011399-bbs2-0036" title="DeeksJJ , HigginsJP , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). We planned to judge heterogeneity as considerable if I<sup>2</sup> statistic was greater than 50% or if the P value in the Chi<sup>2</sup> test was less than 0.10 (<a href="./references#CD011399-bbs2-0036" title="DeeksJJ , HigginsJP , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). However, in the present review we only identified one trial (<a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a>), and we could not asses heterogeneity. </p> </section> <section id="CD011399-sec-0067"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess publication bias by using a funnel plot, which is usually used to illustrate variability between trials in a graphical way. We needed at least 10 trials in order to be able to make judgements about asymmetry and, if asymmetry were present, we would have attempted to explore other causes for it (<a href="./references#CD011399-bbs2-0082" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ2011;343:d4002. [PUBMED: 21784880] ">Sterne 2011</a>). However, in the present review we only identified one trial (<a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a>), and we could not report biases. </p> </section> <section id="CD011399-sec-0068"> <h4 class="title">Data synthesis</h4> <p>We planned to carry out statistical analyses using <a href="./references#CD011399-bbs2-0077" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>. We planned to use fixed‐effect meta‐analysis for combining data where it was reasonable to assume that trials were estimating the same underlying treatment effect. However, in the present review, we only identified one trial (<a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a>), and we could not perform data analysis. </p> <section id="CD011399-sec-0069"> <h5 class="title">Trial sequential analysis</h5> <p>We planned to apply trial sequential analysis as cumulative meta‐analyses are at risk of producing random errors due to sparse data and repetitive testing of the accumulating data (<a href="./references#CD011399-bbs2-0025" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive‐‐Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International journal of epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>;<a href="./references#CD011399-bbs2-0089" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of clinical epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>).To minimize random errors, we planned to calculate the required information size (i.e. the number of participants needed in a meta analysis to detect or reject a certain intervention effect) (<a href="./references#CD011399-bbs2-0089" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of clinical epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>).We planned to perform a meta‐analysis, and base the diversity‐adjusted required information size on the event proportion in the control group; assumption of a plausible RR reduction of 20%. However, in the present review we only identified one trial (<a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a>), and we could not perform a trial sequential analysis. </p> </section> </section> <section id="CD011399-sec-0070"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform subgroup analysis for primary outcomes. If necessary, we planned to perform post hoc subgroup analyses. We planned to specify the reason sufficiently interpreted the results with caution. However in the present review we only identified one trial (<a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a>), and we could not perform subgroup analysis. </p> </section> <section id="CD011399-sec-0071"> <h4 class="title">Sensitivity analysis</h4> <p>If the searches identified sufficient trials, we planned to conduct sensitivity analyses as follows: </p> <p> <ul id="CD011399-list-0008"> <li> <p>including only randomised clinical trials at low risk of bias (<a href="./references#CD011399-bbs2-0036" title="DeeksJJ , HigginsJP , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). As it was unlikely that we would find many trials at low risk of bias in all domains, we chose to focus on three core domains, namely: generation of allocation sequence, allocation concealment, and blinding or masking; </p> </li> <li> <p>repeating the analysis taking attrition bias into consideration.</p> </li> </ul> </p> <p>However, in the present review we only identified one trial (<a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a>), and we could not perform sensitivity analysis by risk of bias. </p> <section id="CD011399-sec-0072"> <h5 class="title">Grading the quality of evidence</h5> <p>The GRADE approach specifies four levels of quality (high, moderate, low and very low), starting from high for randomised clinical trials. We planned to explore the impact of the level of bias by undertaking sensitivity analyses (see <a href="#CD011399-sec-0071">Sensitivity analysis</a>), and we used the GRADE approach in order to produce a 'Summary of findings' table (<a href="./references#CD011399-bbs2-0043" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a>; <a href="./references#CD011399-bbs2-0080" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al. on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2017</a>). We downgraded the quality of evidence depending on the presence of the following factors: </p> <p> <ul id="CD011399-list-0009"> <li> <p>study limitations;</p> </li> <li> <p>inconsistency of results;</p> </li> <li> <p>indirectness of evidence;</p> </li> <li> <p>imprecision;</p> </li> <li> <p>publication bias.</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011399-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011399-sec-0073"></div> <section id="CD011399-sec-0074"> <h3 class="title">Description of studies</h3> <p>See <a href="./full#CD011399-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD011399-sec-0075"> <h4 class="title">Results of the search</h4> <p>We identified only one trial (<a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a>). The search of electronic databases (CENTRAL, MEDLINE, Embase and LILACS) yielded 60 records and the search of other sources identified three records. After removing duplicates and reviewing the titles and abstracts, we discarded 34 citations. We reviewed the full text of 15 studies; 13 did not fulfil the criteria to be included in this systematic review so we excluded them, and one trial is awaiting classification. We contacted the authors of this trial but we could not retrieve the full‐text article (<a href="./references#CD011399-bbs2-0016" title="SerraguiS , YahyaouiM , HassarM , ChkiliT , BouhaddiouiN , SoulaymaniR . A comparison study of two therapeutic protocols for neurosyphilis. Therapie1999;54(5):613‐21. ">Serragui 1999</a>). See <a href="#CD011399-fig-0001">Figure 1</a>. </p> </section> <section id="CD011399-sec-0076"> <h4 class="title">Included studies</h4> <p>We identified one multicenter, parallel‐design trial, which involved 36 participants with syphilis and HIV‐1 infection (<a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a>). Ninety two percent of participants were male (33/36), with a median of age of 34 years. <a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a> compared ceftriaxone (2 g, intravenous (IV) once daily), or penicillin G (4 MU, IV, every 4 hours). Eighteen participants were randomised to receive ceftriaxone for 10 days and 18 participants were randomised to receive penicillin G for 10 days. The trial was conducted in the United States. . See <a href="./references#CD011399-sec-0127" title="">Characteristics of included studies</a> section for details.The outcomes evaluated regarding serological cure were CSF WBC counts,CSF protein concentrations and , regarding clinical cure serum RPR titers. In this clinical trial the authors reported what usually are adverse events as symptoms and signs in the follow‐up of participants. </p> <p><a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a> did not evaluate recurrence of neurosyphilis, time to recovery or quality of life. </p> <p><a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a> was funded by the pharmaceutical industry, and was conducted between October 1991 through April 1994. However, the results were published in 2000. </p> </section> <section id="CD011399-sec-0077"> <h4 class="title">Excluded studies</h4> <p>We excluded 14 studies: four were not clinical trials (<a href="./references#CD011399-bbs2-0006" title="HahnRD , LewisBI , WiggalRH , CrossES . The treatment of neurosyphilis with penicillin and with penicillin plus malaria. British Journal of Venereal Diseases1952;28:41. ">Hahn 1952</a>; <a href="./references#CD011399-bbs2-0009" title="PhilcoxDV , CallananJJ , ForderAA . Treatment of neurosyphilis. A comparison of penicillin regimens. South African Medical Journal1987;72:110‐3. ">Philcox 1987</a>; <a href="./references#CD011399-bbs2-0014" title="StarzyckiZ , MarkiewiczJ , MayerJ , Bogdaszewska‐CzabanowskaJ . Results of the treatment of neurosyphilis with high doses of crystalline and procaine penicillins. Przegla̧d Dermatologiczny1990;77:359‐62. ">Starzycki 1990</a>; <a href="./references#CD011399-bbs2-0004" title="DunawayS , MaxwellC , TantaloL , SahiS , DavisAP , StevensC , et al. Treatment of neurosyphilis: IV penicillin G VS IM procaine penicillin/oral probenecid. Topics in Antiviral Medicine. 2017; Vol. 25, issue 1:319s. ">Dunaway 2017</a>), four were case series reports (<a href="./references#CD011399-bbs2-0005" title="GoldmanD . Neurosyphilis treated with penicillin. Report of 140 cases. British Journal of Venereal Diseases1950;26:102. ">Goldman 1950</a>; <a href="./references#CD011399-bbs2-0007" title="KoppI , RoseAS , SolomonHC . The treatment of late symptomatic neurosyphilis at the Boston Psychopathic Hospital. A study of the results of penicillin therapy in 394 patients treated between February 1944 and March 1948. British Journal of Venereal Diseases1949;25:213. ">Kopp 1949</a>; <a href="./references#CD011399-bbs2-0008" title="OrbánT , LazarovitsL . Results of 5‐year old treatment of neurosyphilitics with penicillin. Wiener Medizinische Wochenschrift1956;106(17):377‐81. OrbánT , LazarovitsL . Results of five years of penicillin treatment of neurosyphilis. British Journal of Venereal Diseases1957;33(1):59‐68. ">Orban 1957</a>; <a href="./references#CD011399-bbs2-0015" title="TempskiJ , OlszewskaZ , HeykoporebskiJ . Evaluation of the treatment of neurosyphilis with penicillin and fever therapy. British Journal of Venereal Diseases1958;34(1):60‐8. ">Tempski 1958</a>), two did not include participants with neurosyphilis (<a href="./references#CD011399-bbs2-0013" title="SmithNH , MusherDM , HuangDB , RodriguezPS , DowellME , AceW , et al. Response of HIV‐infected patients with asymptomatic syphilis to intensive intramuscular therapy with ceftriaxone or procaine penicillin. International Journal of STD &amp; AIDS2004;15:328‐32. ">Smith 2004</a>; <a href="./references#CD011399-bbs2-0011" title="RolfsRT , JoesoefMR , HendershotEF , RompaloAM , AugenbraunMH , ChiuM , et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. New England Journal of Medicine1997;337(5):307‐14. ">Rolfs 1997</a>), three were narrative reviews (<a href="./references#CD011399-bbs2-0002" title="ChesneyLP , ReynoldsFW . Penicillin in treatment of neurosyphilis IV tabes dorsalis. British Journal of Venereal Diseases1949;25:38. ">Chesney 1949</a>; <a href="./references#CD011399-bbs2-0003" title="ClementME , OkekeNL , HicksCB . Treatment of syphilis: a systematic review. JAMA2014;312:1905‐17. ">Clement 2014</a>; <a href="./references#CD011399-bbs2-0012" title="ShortDH , KnoxJM , GlicksmanJ . Neurosyphilis, the search for adequate treatment. A review and report of a study using benzathine penicillin G. Archives of Dermatology1966;93:87‐91. ">Short 1966</a>), and one included two participants with neurosyphilis but did not report any results outcomes regarding those two participants (<a href="./references#CD011399-bbs2-0010" title="PotthoffA , BrockmeyerNH . Randomized, prospective, open‐label study to compare the efficacy of treatment with benzathine penicillin or ceftriaxone in early syphilis in HIV‐infected patients. HIV Medicine2009;10:21. ">Potthoff 2009</a>). See <a href="./references#CD011399-sec-0128" title="">Characteristics of excluded studies</a> section for details. </p> <section id="CD011399-sec-0078"> <h5 class="title">Studies awaiting classification</h5> <p>One trial is awaiting classification (<a href="./references#CD011399-bbs2-0016" title="SerraguiS , YahyaouiM , HassarM , ChkiliT , BouhaddiouiN , SoulaymaniR . A comparison study of two therapeutic protocols for neurosyphilis. Therapie1999;54(5):613‐21. ">Serragui 1999</a>). We only had access to the trial abstract and it was not clear whether it was a clinical trial. We contacted the trial authors to get the full text and we have had no reply yet. See <a href="./references#CD011399-sec-0129" title="">Characteristics of studies awaiting classification</a> for details. </p> </section> <section id="CD011399-sec-0079"> <h5 class="title">Ongoing trials</h5> <p>We did not find any ongoing trials regarding treatment for neurosyphilis in adults.</p> </section> </section> </section> <section id="CD011399-sec-0080"> <h3 class="title">Risk of bias in included studies</h3> <p>We summarised the 'Risk of bias' assessment for <a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a> in <a href="#CD011399-fig-0002">Figure 2</a> and <a href="#CD011399-fig-0003">Figure 3</a>. We have also presented additional details of the trial in the <a href="./references#CD011399-sec-0127" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD011399-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study" data-id="CD011399-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_n/nCD011399-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD011399-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD011399-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_n/nCD011399-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD011399-sec-0081"> <h4 class="title">Random sequence generation</h4> <p>The trial authors reported <a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a> as randomised, but it did not contain a description of the process of sequence generation, therefore, we considered it at unclear risk of bias. </p> </section> <section id="CD011399-sec-0082"> <h4 class="title">Allocation</h4> <p><a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a> did not contain a description of the process of sequence generation, so we considered it at unclear risk of bias. </p> </section> <section id="CD011399-sec-0083"> <h4 class="title">Blinding</h4> <p>We rated <a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a> as being at unclear risk of bias for blinding because there was insufficient information about masking of participants and outcome evaluators to permit us to make a judgment of 'low risk' or 'high risk'. </p> </section> <section id="CD011399-sec-0084"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a> initially randomised 36 participants but the trial authors reported an overall withdrawal of 17% (6/36). In the group receiving ceftriaxone, four of 18 participants were not included in the analysis, and in the group receiving penicillin G, two of 18 participants were not analysed. In both groups the participants were not included in the analysis due to loss to follow‐up, so we considered this trial as having a high risk of attrition bias. </p> </section> <section id="CD011399-sec-0085"> <h4 class="title">Selective reporting</h4> <p>The trial authors reported baseline characteristics for the 30 participants who received ceftriaxone or penicillin G for neurosyphilis treatment. However, the trial authors' report of the proportion of participants with improved CSF‐VDRL RPR titres was imprecise regarding the period of time over which the tests took place. Also, the trial authors only reported results in CSF‐VDR after treatment in seven participants who received ceftriaxone and in seven participants who received penicillin G. Regarding RPR titres, the trial authors only reported results after treatment in 10 participants receiving ceftriaxone and 15 participants receiving penicillin G. Therefore, we considered this trial to be at high risk of selective reporting bias. </p> </section> <section id="CD011399-sec-0086"> <h4 class="title">Other potential sources of bias</h4> <p>The trial authors did not describe the procedure they used to calculate a sample size, which generated a design bias (<a href="./references#CD011399-bbs2-0075" title="PortaM . A Dictionary of Epidemiology. Oxford: Oxford University Press, 2014:79. ">Porta 2014</a>). Additionally this study was funded by the pharmaceutical Industry. </p> </section> </section> <section id="CD011399-sec-0087"> <h3 class="title" id="CD011399-sec-0087">Effects of interventions</h3> <p>See: <a href="./full#CD011399-tbl-0001"><b>Summary of findings for the main comparison</b> Ceftriaxone compared to penicillin G for neurosyphilis</a> </p> <p>Results are based on one study (<a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a>). See <a href="./full#CD011399-tbl-0001">summary of findings Table for the main comparison</a> for details of grading the quality of evidence. </p> <section id="CD011399-sec-0088"> <h4 class="title">Ceftriazone versus penicillin G</h4> <section id="CD011399-sec-0089"> <h5 class="title">Primary outcomes</h5> <section id="CD011399-sec-0090"> <h6 class="title">Serological cure</h6> <p><a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a>, our single included trial, compared ceftriaxone with penicillin G and showed inconclusive effects regarding serological cure, with three of 18 participants (16%) in the ceftriaxone group versus two of 18 participants (11%) in the penicillin G group reporting serological cure (RR 1.50, 95% CI 0.28 to 7.93; 1 study, 36 participants, very low‐quality evidence due to risk of bias, inconsistency and imprecision; <a href="./references#CD011399-fig-0004" title="">Analysis 1.1</a>). Although <a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a> reported an intention‐to‐treat analysis in the methods section, the results regarding serological cure were reported only in seven participants who received ceftriaxone and seven participants who received penicillin G. </p> </section> <section id="CD011399-sec-0091"> <h6 class="title">Clinical cure</h6> <p><a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a> found inconclusive evidence comparing ceftriaxone (8/18 (44%)), versus penicillin (2/18 (11%)), in terms of clinical cure (RR 4.00, 95% CI 0.98 to 16.30; 1 study, 36 participants, very low‐quality evidence due to risk of bias, inconsistency and imprecision; <a href="./references#CD011399-fig-0005" title="">Analysis 1.2</a>). Although <a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a> reported an intention‐to‐treat analysis in the methods section, the results regarding clinical cure were reported only in 10 participants who received ceftriaxone and 15 participants who received penicillin G. </p> </section> <section id="CD011399-sec-0092"> <h6 class="title">Adverse events</h6> <p>In <a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a>, the trial authors reported symptoms and signs in the included participants as clinical characteristics. We did not consider them as adverse events, so, as a result, we considered that this trial did not report the measurement of adverse events as a primary outcome. We considered this as inappropriately reported adverse events. </p> </section> </section> <section id="CD011399-sec-0093"> <h5 class="title">Secondary outcomes</h5> <section id="CD011399-sec-0094"> <h6 class="title">Recurence of neurosyphilis</h6> <p><a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a> did not provide information about this outcome. </p> </section> <section id="CD011399-sec-0095"> <h6 class="title">Time to recovery</h6> <p><a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a> did not provide information about this outcome. </p> </section> <section id="CD011399-sec-0096"> <h6 class="title">Quality of life</h6> <p><a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a> did not provide information about this outcome. </p> </section> <section id="CD011399-sec-0097"> <h6 class="title">All‐cause withdrawals</h6> <p>There was no difference between the ceftriaxone group (4/18 (22%)), compared with the penicillin G group (2/18 (11%)), with respect to all‐cause withdrawals (RR 2.00, 95% CI 0.42 to 9.58; very low quality evidence due to limitations in the trial design and execution of the trial, with an incomplete data report; <a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a>; <a href="./references#CD011399-fig-0006" title="">Analysis 1.3</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011399-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011399-sec-0098"></div> <section id="CD011399-sec-0099"> <h3 class="title" id="CD011399-sec-0099">Summary of main results</h3> <p>One trial met the inclusion criteria for this review (<a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a>). The trial was conducted in the USA and its aim was to compare the responses of HIV‐infected patients to treatment for neurosyphilis with endovenous ceftriaxone or endovenous penicillin. This trial compared ceftriaxone (2 g IV once daily for 10 days), versus penicillin G (4 MU IV every 4 hours for 10 days), as treatment for neurosyphilis. The study included 18 participants in each group; the trial authors were not specific regarding the randomisation method and blinding. Although they stated that the analysis was by intention‐to‐treat, they reported results regarding serological cure in seven participants from each group, and for clinical cure they reported data in 10 participants receiving ceftriaxone and in 15 participants receiving penicillin. Due to the above, we judged the risk of bias to be unclear in the domains of random sequence generation, allocation concealment, blinding of participants and blinding of outcome assessors; and as high risk in the domains of incomplete data, selective reporting and other biases. Although the proportion of participants who achieved clinical and serological cure was higher in the group that received ceftriaxone, due to incomplete evidence it was not possible to affirm that there is a difference between treatment with ceftriaxone or Penicillin G for neurosyphilis in adults. In addition to the limitations of the quality of the evidence, we cannot be sure about the differences between treatments. Also, the trial did not report adverse events appropriately. We rated the quality of the evidence as very low due to high risk of bias and imprecision issues. </p> </section> <section id="CD011399-sec-0100"> <h3 class="title" id="CD011399-sec-0100">Overall completeness and applicability of evidence</h3> <p>The review found inconclusive evidence to support or refute the use of ceftriaxone for treating people with neurosyphilis. This conclusion is based on one very small trial with flawed methodology, conducted in participants with HIV infection complicated by neurosyphilis (<a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a>). The trial authors themselves pointed out that there were severe differences between the two arms that limited the ability to make useful comparisons (<a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a>). It has been pointed out that simple randomisation may not prevent bias in a smaller trial (<a href="./references#CD011399-bbs2-0069" title="NguyenTL , CollinsGS , LamyA , DevereauxPJ , DauresJP , LandaisP , et al. Simple randomization did not protect against bias in smaller trials. Journal of Clinical Epidemiology2017;84:105‐13. [PUBMED: 28257927] ">Nguyen 2017</a>; <a href="./references#CD011399-bbs2-0079" title="SavovicJ , JonesH , AltmanD , HarrisR , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta‐epidemiological studies. Health Technology Assessment (Winchester, England)2012;16(35):1‐82. [PUBMED: 22989478] ">Savovic 2012</a>). </p> <p>Despite all limitations, <a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a> suggested that intravenous ceftriaxone could be an alternative to penicillin G for people with neurosyphilis; but it could be understood as a 'Texas sharpshooter fallacy', where the trial authors ignored differences but addressed similarities. Also, it is known that small trials could show larger benefits (<a href="./references#CD011399-bbs2-0092" title="ZhangZ , XuX , NiH . Small studies may overestimate the effect sizes in critical care meta‐analyses: a meta‐epidemiological study. Critical Care (London, England)2013;17(1):R2. ">Zhang 2013</a>).<br/> <br/> One limitation of the randomised clinical trial included in this systematic review was the lack of consistency in the measurement of the outcomes recorded as baseline characteristics, due to the fact that not all participants included in the trial received the same tests (<a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a>). We noticed that the outcomes measured in <a href="./references#CD011399-bbs2-0001" title="MarraCM , BoutinP , McArthurJC , HurwitzS , SimpsonPA , HaslettJA , et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus‐infected individuals. Clinical Infectious Diseases2000;30(3):540‐4. [PUBMED: 10722441] ">Marra 2000</a> could be affected by factors such as the methods used to measure the laboratory outcomes at the beginning of the treatment and during its follow‐up, and the measurements of VDRL and RPR at baseline. We cannot know if the data reported here can be applied in other populations with other types of availability of resources to treat neurosyphilis, or even people without HIV. The lack of studies that address additional interventions limits our ability to make a clear statement related to treatment for neurosyphilis. At the same time, we cannot make any statement regarding the safety of the treatment for neurosyphilis due to the absence of adverse events in the report. In addition to the participants that did not finish the study, the trial authors were not able to measure CSF‐VDRL and RPR titres in all participants who finished the trial, which is why we consider that those participants with unquantified CSF‐VDRL and RPR should be considered as withdrawals from the trial. </p> </section> <section id="CD011399-sec-0101"> <h3 class="title" id="CD011399-sec-0101">Quality of the evidence</h3> <p>We used the GRADE approach in order to evaluate the quality of the evidence (<a href="./references#CD011399-bbs2-0043" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a>; <a href="./references#CD011399-bbs2-0080" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al. on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2017</a>). We downgraded the quality of the evidence by one level due to risk of bias. We downgraded by two levels due to imprecision because this study had a small sample size and very low number of events, which had an impact on the precision of the effect estimates, since not all the participants received the same test to establish serological cure and clinical cure, and adverse events were inappropriately reported. We did not downgrade for indirectness and publication bias. </p> <p>See <a href="./full#CD011399-tbl-0001">summary of findings Table for the main comparison</a> for details. </p> </section> <section id="CD011399-sec-0102"> <h3 class="title" id="CD011399-sec-0102">Potential biases in the review process</h3> <p>We performed an exhaustive search to identify and retrieve all published and unpublished clinical trials for the treatment of neurosyphilis in adults, unfortunately only one study met our inclusion criteria. </p> <p>In all of the procedures in this review we followed the guidelines in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011399-bbs2-0046" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), to prevent any bias throughout the review. We performed a wide search for trials, contacting trial authors, and locating all the full texts in order to develop a complete review of trials. We did not limit the search by language or date. We considered the probability of missing trials as low despite only having identified one trial to be included in our review. In addition, we tried to contact the authors from the trial awaiting classification (<a href="./references#CD011399-bbs2-0016" title="SerraguiS , YahyaouiM , HassarM , ChkiliT , BouhaddiouiN , SoulaymaniR . A comparison study of two therapeutic protocols for neurosyphilis. Therapie1999;54(5):613‐21. ">Serragui 1999</a>), however we could not obtain a response from them in order to determine the eligibility of this trial for inclusion. </p> </section> <section id="CD011399-sec-0103"> <h3 class="title" id="CD011399-sec-0103">Agreements and disagreements with other studies or reviews</h3> <p>The narrative review published by <a href="./references#CD011399-bbs2-0003" title="ClementME , OkekeNL , HicksCB . Treatment of syphilis: a systematic review. JAMA2014;312:1905‐17. ">Clement 2014</a>, based on observational and experimental studies, suggests that people with neurosyphilis should be managed with penicillin, and ceftriaxone should be used for people who are allergic to penicillin. However, the authors stated that the evidence of its efficacy is still limited (<a href="./references#CD011399-bbs2-0003" title="ClementME , OkekeNL , HicksCB . Treatment of syphilis: a systematic review. JAMA2014;312:1905‐17. ">Clement 2014</a>). Based on expert consensus, the CDC guidelines for Sexually Transmitted Diseases Treatment Guidelines recommend that the treatment for neurosyphilis should be aqueous crystalline penicillin G and, as an alternative treatment, procaine penicillin G or probenecid (<a href="./references#CD011399-bbs2-0027" title="Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. www.cdc.gov/std/syphilis/default.htm accessed (18 September 2018). ">CDC 2015</a>). In our review we did not find evidence to support ceftriaxone use or other antibiotic interventions to treat neurosyphilis in adults. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011399-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/urn:x-wiley:14651858:media:CD011399:CD011399-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_t/tCD011399-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow of information through the different phases of the review" data-id="CD011399-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_n/nCD011399-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow of information through the different phases of the review</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/full#CD011399-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_n/nCD011399-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011399-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/urn:x-wiley:14651858:media:CD011399:CD011399-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_t/tCD011399-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study" data-id="CD011399-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_n/nCD011399-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/full#CD011399-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_n/nCD011399-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011399-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/urn:x-wiley:14651858:media:CD011399:CD011399-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_t/tCD011399-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD011399-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_n/nCD011399-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/full#CD011399-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_n/nCD011399-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011399-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/urn:x-wiley:14651858:media:CD011399:CD011399-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_t/tCD011399-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ceftriaxone versus penicillin G, Outcome 1 Serological cure." data-id="CD011399-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_n/nCD011399-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Ceftriaxone versus penicillin G, Outcome 1 Serological cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/references#CD011399-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_n/nCD011399-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011399-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/urn:x-wiley:14651858:media:CD011399:CD011399-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_t/tCD011399-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ceftriaxone versus penicillin G, Outcome 2 Clinical cure." data-id="CD011399-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_n/nCD011399-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Ceftriaxone versus penicillin G, Outcome 2 Clinical cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/references#CD011399-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_n/nCD011399-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011399-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/urn:x-wiley:14651858:media:CD011399:CD011399-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_t/tCD011399-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ceftriaxone versus penicillin G, Outcome 3 All causes of withdrawals." data-id="CD011399-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_n/nCD011399-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Ceftriaxone versus penicillin G, Outcome 3 All causes of withdrawals.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/references#CD011399-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/media/CDSR/CD011399/image_n/nCD011399-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011399-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ceftriaxone compared to penicillin G for neurosyphilis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ceftriaxone compared to penicillin G for neurosyphilis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with neurosyphilis<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> ceftriaxone<br/> <b>Comparison:</b> penicillin G </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with penicillin G</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ceftriaxone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serological cure</b><br/> assessed by decrease in the CSF VDRL titre<br/> Follow‐up: range 14 weeks‐52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000<br/> (31 to 881) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.50<br/> (0.28 to 7.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysis performed by ITT analysis. Trial only reported CSF decrease in 2 of 7 participants receiving ceftriaxone and 2 of 7 receiving penicillin </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical cure</b><br/> assessed by RPR decrease<br/> Follow‐up: range 14 weeks‐52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000<br/> (109 to 1811) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.00<br/> (0.98 to 16.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysis performed by ITT analysis. Trial reported improvement in RPR titres in 8 of 10 participants receiving ceftriaxone and 2 of 15 receiving penicillin </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b><br/> Any untoward medical occurrence regarding medications<br/> follow‐up: range 1 week‐52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial evaluated symptoms and signs in the included participants, but these were clinical characteristics of participants, and not defined as adverse events </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence of neurosyphilis</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>( studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to recovery</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>( studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>( studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals</b><br/> Follow‐up: range 1 week‐52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000<br/> (47 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.00<br/> (0.42 to 9.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <br/> <b>CI:</b> Confidence interval; <b>CSF:</b> cerebrospinal fluid; <b>ITT:</b> intention‐to‐treat; <b>RPR:</b> rapid plasma reagin; <b>RR:</b> Risk ratio; <b>VDRL</b>: Venereal Disease Research Laboratory </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels due to limitations in the trial design and execution of trials.<br/> <sup>2</sup>Downgraded two levels due to few events and incomplete data regarding outcome, 95% confidence interval was between 0.28 and 7.93.<br/> <sup>3</sup>Not all the participants received the exact same tests to determine microbiological and clinical cure. Also, the sample size was very small and there was a very low number of events, which had an impact on the precision of the effect estimates.<br/> <sup>4</sup>Downgraded two levels due to the small sample size and very low number of events, which had an impact on the precision of the effect estimates<br/> <sup>5</sup>Downgraded two levels due to few events and incomplete data regarding outcome, 95% confidence interval was between 0.98 and 16.30. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ceftriaxone compared to penicillin G for neurosyphilis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/full#CD011399-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011399-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ceftriaxone versus penicillin G</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serological cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.28, 7.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [0.98, 16.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All causes of withdrawals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.42, 9.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ceftriaxone versus penicillin G</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011399.pub2/references#CD011399-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011399.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011399-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011399-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011399-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD011399-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD011399-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD011399-note-0004">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011399-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011399\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011399\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011399\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011399\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011399\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011399\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011399\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011399\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011399\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011399\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011399\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011399\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011399\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011399\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011399\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011399\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011399\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011399\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011399.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011399.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011399.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011399.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011399.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728580642"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011399.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728580646"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011399.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec7f3f81ef431',t:'MTc0MDcyODU4MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 